Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091182 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
A Phase 2 study of Childhood Central Nervous System Germ Cell Tumor and Childhood High-grade Cerebral Astrocytoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT00091182: Completed Phase 2 study of Childhood Central Nervous System Germ Cell Tumor and Childhood High-grade Cerebral Astrocytoma, sponsored by National Cancer Institute (NCI).
NCT00091182 is a Phase 2 study of Childhood Central Nervous System Germ Cell Tumor and Childhood High-grade Cerebral Astrocytoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 180 participants, above the 47-participant average among 3 other Childhood Central Nervous System Germ Cell Tumor trials with a reported enrollment target (283% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091182, a Phase 2 study of Childhood Central Nervous System Germ Cell Tumor and Childhood High-grade Cerebral Astrocytoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
Primary Outcome
Response rate and confidence intervals will be constructed according to the method of Chang and O'Brien.
Conditions Studied
Interventions
- DRUG oxaliplatin
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2004-10 |
| Phase | Phase 2 |
What the finished NCT00091182 record still lists
NCT00091182 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 47-participant average among 3 other Childhood Central Nervous System Germ Cell Tumor trials with a reported enrollment target (283% higher).
The record links to 10 conditions, with Childhood Central Nervous System Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which oxaliplatin is the first listed.
NCT00091182 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00091182 about?
NCT00091182 is a clinical study titled "Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment". This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00091182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2004-10.
What conditions does trial NCT00091182 study?
This clinical trial studies the following conditions: Childhood Central Nervous System Germ Cell Tumor, Childhood High-grade Cerebral Astrocytoma, Childhood Teratoma, Childhood Hepatocellular Carcinoma, Childhood Extragonadal Germ Cell Tumor.
What interventions are being tested in trial NCT00091182?
The interventions under investigation include: oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00091182?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00091182 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Childhood Central Nervous System Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
COMPLETED · Phase 1
-
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
COMPLETED · Phase 1
-
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia